Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma

Cancer Science

Volumn 102, Issue 7, 2011, Pages 1424-1431

  Komohara, Yoshihiro ^a   Hasita, Horlad ^a   Ohnishi, Koji ^a   Fujiwara, Yukio ^a   Suzu, Shinya ^b   Eto, Masatoshi ^a   Takeya, Motohiro ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD204 ANTIGEN; COLONY STIMULATING FACTOR 1; STAT3 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CELL INTERACTION; CLEAR CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CARCINOMA, RENAL CELL; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; HUMANS; KIDNEY NEOPLASMS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; SCAVENGER RECEPTORS, CLASS A; STAT3 TRANSCRIPTION FACTOR;

EID: 79959228665     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01945.x     Document Type: Article

References (45)

1. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
2. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-65.
3. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-12.
4. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
5. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209-12.
6. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-86.
7. Hagemann T, Biswas SK, Lawrence T, Sica A, Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 2009; 113: 3139-46.
8. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
9. Komohara Y, Hirahara J, Horikawa T et al. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006; 54: 763-71.
10. Niino D, Komohara Y, Murayama T et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 2010; 60: 278-83.
11. Hasita H, Komohara Y, Okabe H et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010; 101: 1913-19.
12. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216: 15-24.
13. Jensen TO, Schmidt H, Moller HJ et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009; 27: 3330-7.
14. Clear AJ, Lee AM, Calaminici M et al. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood 2010; 115: 5053-6.
15. Espinosa I, Beck AH, Lee CH et al. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol 2009; 174: 2347-56.
16. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007; 5: 62.
17. Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol 2009; 16: 801-7.
18. Hamada I, Kato M, Yamasaki T et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res 2002; 22: 4281-4.
19. Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 2005; 174: 461-5.
20. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-52.
21. Lin EY, Nguyen AV, Russell RG et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193: 727-40.
22. Hagemann T, Wilson J, Burke F et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006; 176: 5023-32.
23. Stein J, Borzillo GV, Rettenmier CW. Direct stimulation of cells expressing receptors for macrophage colony-stimulating factor (CSF-1) by a plasma membrane-bound precursor of human CSF-1. Blood 1990; 76: 1308-14.
24. Douglass TG, Driggers L, Zhang JG et al. Macrophage colony stimulating factor: not just for macrophages anymore! A gateway into complex biologies. Int Immunopharmacol 2008; 8: 1354-76.
25. Yao GQ, Wu JJ, Sun BH, Troiano N, Mitnick MA, Insogna K. The cell surface form of colony-stimulating factor-1 is biologically active in bone in vivo. Endocrinology 2003; 144: 3677-82.
26. Grignon DJ, Eble JN, Bonsib SM, Moch H. Clear cell renal carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization classification of tumours: Pathology and Genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004.
27. Chihara T, Suzu S, Hassan R et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ 2010; 49: 662-71.
28. Travaglione S, Falzano K, Fabbri A et al. Epithelial cells and expression of the phagocytic marker CD68: scavenging of apoptotic bodies following Rho activation. Toxcol in Vitro 2002; 16: 405-11.
29. Sica A, Schioppa T, Mantovani A et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-27.
30. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-73.
31. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008; 84: 623-30.
32. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008; 267: 204-15.
33. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
34. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 2002; 168: 762-5.
35. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69: 2506-13.
36. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-57.
37. Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91: 4070-6.
38. Hagemann T, Lawrence T. Investigating macrophage and malignant cell interactions in vitro. Methods Mol Biol 2009; 512: 325-32.
39. Ikemoto S, Yoshida N, Narita K et al. Role of tumor-associated macrophages in renal cell carcinoma. Oncol Rep 2003; 10: 1843-9.
40. Ikemoto S, Narita K, Yoshida N et al. Effects of tumor necrosis factor alpha in renal cell carcinoma. Oncol Rep 2003; 10: 1947-55.
41. Zheng Y, Cai Z, Wang S et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009; 114: 3625-8.
42. Ide H, Seligson DB, Memarzadeh S et al. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci U S A 2002; 99: 14404-9.
43. Richardsen E, Sorbye SW, Crowe JP, Yang JL, Busund LT. Expression of M-CSF and CSF-1R is correlated with histological grade in soft tissue tumors. Anticancer Res 2009; 29: 3861-6.
44. Scholl SM, Pallud C, Beuvon F et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994; 86: 120-6.
45. Patsialou A, Wyckoff J, Wang Y, Goswami S, Stanley ER, Condeelis JS. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res 2009; 69: 9498-506.